Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 56
Rev. Hosp. Ital. B. Aires (2004) ; 39(4): 146-148, dic. 2019. ilus
Article in Spanish | LILACS | ID: biblio-1099838


Los anticuerpos monoclonales que inhiben los puntos de control PD-1 y CTLA-4 se usan actualmente en el tratamiento del melanoma y cáncer metastásico de pulmón de células no pequeñas, entre otros. Se refiere el caso de una paciente con cáncer de pulmón en tratamiento con pembrolizumab. La paciente se presentó con edema facial y parálisis facial periférica. En el laboratorio se observó la hormona tirotrofina (TSH) elevada y se llegó al diagnóstico de hipotiroidismo por pembrolizumab. Inició tratamiento con levotiroxina con mejoría clínica. Se presenta este caso por el importante papel del dermatólogo en el manejo multidisciplinario del paciente oncológico. (AU)

Monoclonal antibodies that inhibit PD-1 and CTLA-4 control points are currently used in the treatment of melanoma and metastatic non-small cell lung cancer, among others. The case of a patient, with lung cancer being treated with Pembrolizumab. The patient was presented with facial edema and peripheral facial paralysis and in the laboratory the elevated hormone Tyrotrophin (TSH) was observed, the diagnosis of pembrolizumab hypothyroidism was reached. She started treatment with levothyroxine with clinical improvement. This case is presented by the important role of the dermatologist in the multidisciplinary management of the cancer patient. (AU)

Humans , Female , Middle Aged , M Phase Cell Cycle Checkpoints/drug effects , Immunotherapy/adverse effects , Antibodies, Monoclonal/adverse effects , Thyroxine/therapeutic use , Brain Neoplasms/complications , Brain Neoplasms/drug therapy , Thyrotropin/analysis , Carboplatin/administration & dosage , Carcinoma, Non-Small-Cell Lung/complications , Carcinoma, Non-Small-Cell Lung/drug therapy , Tumor Suppressor Proteins/drug effects , Dermatology , Facial Injuries , Facial Paralysis , CTLA-4 Antigen/drug effects , CTLA-4 Antigen/physiology , Programmed Cell Death 1 Receptor/drug effects , Programmed Cell Death 1 Receptor/physiology , Pemetrexed/administration & dosage , Melanoma/complications , Melanoma/drug therapy , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/therapeutic use , Neoplasm Metastasis/drug therapy
Arch. endocrinol. metab. (Online) ; 60(6): 601-604, Nov.-Dec. 2016. tab, graf
Article in English | LILACS | ID: biblio-827794


SUMMARY Resistance to thyroid hormone (RTH) coexisting with ectopic thyroid is rare. Here we report a case of RTH with ectopic thyroid. A ten-year-old girl had been misdiagnosed as congenital hypothyroidism and treated with levothyroxine since she was born. Ten-year follow-up showed that the elevated thyrotropin was never suppressed by levothyroxine and no signs indicating hyperthyroidism or hypothyroidism despite elevated FT3 and FT4 levels. Therefore the girl developed no defects in physical and cognitive development. Pituitary adenoma was excluded by magnetic resonance imaging. Ultrasonography did not find the thyroid gland in the normal place, while the thyroid scan found a large lingual thyroid gland. The octreotide inhibition test showed a reduction in thyrotropin by 41.98%. No mutation was detected in the thyroid hormone receptor (THR) β, THRα, thyrotropin receptor (TSHR), and GNAS1 genes. To our knowledge, it is an interesting RTH case coexisting with lingual thyroid.

Humans , Female , Child , Receptors, Thyroid Hormone/genetics , Thyroid Hormone Resistance Syndrome/complications , Thyroid Dysgenesis/complications , Thyroxine/therapeutic use , Time Factors , Tongue Diseases/diagnostic imaging , DNA/isolation & purification , Thyrotropin/analysis , DNA Mutational Analysis , Follow-Up Studies , Thyroid Hormone Resistance Syndrome/genetics , Congenital Hypothyroidism/diagnosis , Diagnostic Errors , Thyroid Dysgenesis/genetics , Thyroid Dysgenesis/diagnostic imaging
Article in English | WPRIM | ID: wpr-91726


BACKGROUND/AIMS: Hypothyroidism is reported to contribute to the development of nonalcoholic fatty liver disease (NAFLD). We compared the risk of the development of NAFLD among three groups with different thyroid hormonal statuses (control, subclinical hypothyroidism, and overt hypothyroidism) in a 4-year retrospective cohort of Korean subjects. METHODS: Apparently healthy Korean subjects without NAFLD and aged 20-65 years were recruited (n=18,544) at health checkups performed in 2008. Annual health checkups were applied to the cohort for 4 consecutive years until December 2012. Based on their initial serum-free thyroxine (fT4) and thyroid-stimulating hormone (TSH) levels, they were classified into control, subclinical hypothyroidism (TSH >4.2 mIU/L, normal fT4), and overt hypothyroidism (TSH >4.2 mIU/L, fT4 <0.97 ng/dL) groups. NAFLD was diagnosed on the basis of ultrasonography findings. RESULTS: NAFLD developed in 2,348 of the 18,544 subjects, representing an overall incidence of 12.7%: 12.8%, 11.0%, 12.7% in the control, subclinical hypothyroidism, and overt hypothyroidism groups, respectively. The incidence of NAFLD did not differ significantly with the baseline thyroid hormonal status, even after multivariate adjustment (subclinical hypothyroidism group: hazard ratio [HR]=0.965, 95% confidence interval [CI]=0.814-1.143, P=0.67; overt hypothyroidism group: HR=1.255, 95% CI=0.830-1.899, P=0.28). CONCLUSIONS: Our results suggest that the subclinical and overt types of hypothyroidism are not related to an increased incidence of NAFLD.

Adult , Aged , Cohort Studies , Female , Follow-Up Studies , Humans , Hypothyroidism/complications , Incidence , Kaplan-Meier Estimate , Liver/diagnostic imaging , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/complications , Proportional Hazards Models , Retrospective Studies , Risk Factors , Thyrotropin/analysis , Thyroxine/analysis
Arq. bras. endocrinol. metab ; 58(9): 906-911, 12/2014. tab, graf
Article in English | LILACS | ID: lil-732193


Objective To determine how endocrinologists in Latin America deal with clinical case scenarios related to hypothyroidism and pregnancy. Materials and methods In January 2013, we sent an electronic questionnaire on current practice relating to management of hypothyroidism in pregnancy to 856 members of the Latin American Thyroid Society (LATS) who manage pregnant patients with thyroid disease. Subsequently, we have analyzed responses from physician members. Results Two hundred and ninety-three responders represent clinicians from 13 countries. All were directly involved in the management of maternal hypothyroidism and 90.7% were endocrinologists. The recommendation of a starting dose of L-thyoxine for a woman diagnosed with overt hypothyroidism in pregnancy, preconception management of euthyroid women with known thyroid autoimmunity and approach related to ovarian hyperstimulation in women with thyroid peroxidase antibodies were widely variable. For women with known hypothyroidism, 34.6% of responders would increase L-thyroxine dose by 30-50% as soon as pregnancy is confirmed. With regard to screening, 42.7% of responders perform universal evaluation and 70% recommend TSH < 2.5 mUI/L in the first trimester and TSH < 3 mUI/L in the second and third trimester as target results in known hypothyroid pregnant women. Conclusion Deficiencies in diagnosis and management of hypothyroidism during pregnancy were observed in our survey, highlighting the need for improvement of specialist education and quality of care offered to patients with thyroid disease during pregnancy in Latin America. Arq Bras Endocrinol ...

Objetivo Determinar, na América Latina, como os endocrinologistas lidam com cenários clínicos relacionados ao hipotireoidismo durante a gravidez. Materiais e métodos Em Janeiro de 2013, foi enviado, para 856 membros da Sociedade Latino-Americana de Tireoide (LATS), um questionário eletrônico sobre práticas relacionadas ao manejo do hipotireoidismo durante a gestação. Subsequentemente, as respostas foram analisadas. Resultados Duzentos e noventa e três médicos, de 13 países, responderam ao questionário. Todos estavam diretamente envolvidos no manejo de hipotireoidismo materno e 90,7% eram endocrinologistas. As recomendações de iniciar terapia com levotiroxina para uma mulher com hipotireoidismo franco durante a gravidez e o manejo na fase de pré-concepção de pacientes eutireoidianas com conhecida autoimunidade em hiperestimulação ovariana variaram amplamente. Para mulheres com hipotireoidismo conhecido, apenas 34,6% dos respondedores aumentariam a dose de levotiroxina em 30-50% assim que a gravidez fosse confirmada. Em relação ao rastreamento, 42,7% dos respondedores realizam avaliação universal. Setenta por cento recomendam TSH < 2,5 mUI/L no primeiro trimestre e TSH < 3 mUI/L no terceiro trimestre como alvos. Conclusão Observamos problemas no diagnóstico e manejo do hipotireoidismo durante a gestação, enfatizando a necessidade, na América Latina, de melhoria na educação médica continuada em áreas como tireoiodopatias na gestação. Arq Bras Endocrinol Metab. ...

Adult , Female , Humans , Pregnancy , Hypothyroidism/diagnosis , Hypothyroidism/drug therapy , Practice Patterns, Physicians'/statistics & numerical data , Pregnancy Complications/diagnosis , Pregnancy Complications/drug therapy , Surveys and Questionnaires , Europe , Latin America , Mass Screening , Practice Guidelines as Topic , Societies, Medical/statistics & numerical data , Thyroid Gland/immunology , Thyrotropin/analysis , Thyroxine/therapeutic use
Rev. cuba. endocrinol ; 25(2): 87-103, Mayo.-ago. 2014.
Article in Spanish | LILACS, CUMED | ID: lil-727594


Introducción: La enfermedad tiroidea nodular constituye un problema de salud en la población adulta por su alta prevalencia. Su diagnóstico se ha favorecido en las últimas décadas como consecuencia de la realización del ultrasonido del tiroides. La provincia de Sancti Spíritus, no disponía de investigaciones previas para analizar la problemática de esta enfermedad y del bocio difuso en las personas adultas, por lo que un estudio de prevalencia se realizó en la ciudad de Jatibonico. Objetivos: determinar la prevalencia de la enfermedad tiroidea nodular y del bocio difuso en la población adulta de 3 consultorios del área urbana de Jatibonico; así como precisar en las personas con enfermedad tiroidea nodular y con bocio difuso, sus antecedentes personales y familiares, el cuadro clínico de presentación, los signos ultrasonográficos y el valor de la hormona estimulante del tiroides. Métodos: el universo de estudio lo constituyó una población de 18 años o más de edad de ambos sexos, pertenecientes a 3 consultorios escogidos al azar del área urbana de Jatibonico (n= 6 126 personas). La muestra estimada para un intervalo de confianza del 95 por ciento fue de 337 personas, y se logró encuestar a 405 sujetos. A la totalidad se les realizó un ultrasonido del tiroides. A 277 personas se les determinó la hormona estimulante del tiroides. Las personas fueron clasificadas con y sin enfermedad tiroidea; y a su vez, esta última, fue subclasificada en enfermedad tiroidea nodular y bocio difuso. Resultados: la prevalencia de la enfermedad tiroidea en la población estudiada fue de 41,97 por ciento (IC- 95 por ciento: 37,17-46,77 por ciento). Al individualizarla, la enfermedad tiroidea nodular se halló en el 36,79 por ciento (IC- 95 por ciento: 32,09-41,48 por ciento) y el bocio difuso en el 5,18 por ciento (IC- 95 por ciento: 3,02-7,33 por ciento) respectivamente. Los pacientes con enfermedad tiroidea, en su mayoría, se manifestaban asintomáticos (85,3 por ciento) y se distribuyeron en todos los grupos de edades, pero con un ligero predominio en las féminas. La hormona estimulante del tiroides elevada (32,85 por ciento) y subnormal (7,58 por ciento) se constataron en los pacientes estudiados. Conclusión: en la población estudiada, la prevalencia de la enfermedad tiroidea nodular fue mayor que la del bocio difuso(AU)

Introduction: Thyroid nodule disease is a health problem in the adult population due to its high incidence. The diagnosis has improved in the last few decades as a result of the thyroid computer tomography. Previous research studies to analyze the situation of this disease and of diffuse goiter in the adult population did not exist in Sancti Spiritus province, so the prevalence study was conducted in Jatibonico city. Objective: to determine the prevalence of the thyroid nodule disease and of diffuse goiter in the adult populations from 3 physician's offices located in Jatibonico urban area as well as to determine the personal and family histories, the clinical picture of presentation, the ultrasonographic signs and the value of the thyroid-stimulating hormone in those people with thyroid nodule and diffuse goiter. Methods: the universe of study was an 18 years-old and over population of both sexes from 3 randomly selected physician's offices located in the urban area of Jatibonico (n= 6 126 people). The estimated sample for 95 % confidence interval was 337 persons and a total number of 405 individuals were surveyed. All of them were performed thyroid computer tomography. The thyroid-stimulating hormone was detected in 277 people. They were then classified into subjects having and not having the disease, and at the same time, there was sub-classification into thyroid nodule disease and diffuse goiter. Results: the prevalence of thyroid disease in the studied population was 41.97 percent (CI- 95 percent: 37.17-46.77 percent). The sub-classification yielded the presence of thyroid nodule disease in 36.79 percent of subjects (CI- 95 percent: 32.09-41.48 percent) and of diffuse goiter in 5.18 percent (CI- 95 percent: 3.02-7.33 percent), respectively. The majority of patients suffering from this disease was asymptomatic (85.3 percent) and distributed into all the age groups, with slight predominance of females. The high (32.85 percent) and the subnormal (7.58 percent) thyroid-stimulating hormones were detected in the studied patients. Conclusions: in the study population, the prevalence of the thyroid nodule disease was higher than that of the diffuse goiter(AU)

Humans , Male , Female , Thyroid Diseases/diagnostic imaging , Thyrotropin/analysis , Thyroid Nodule/epidemiology , Goiter, Nodular/epidemiology , Epidemiology, Descriptive , Cross-Sectional Studies/methods
J. bras. med ; 102(3)jul. 2014.
Article in Portuguese | LILACS | ID: lil-719969


A população mundial está envelhecendo, e o interesse pelo estudo da associação entre disfunções tireoidianas e o processo de envelhecimento também. Existem evidências de que os níveis de TSH são mais elevados na população idosa, com uma relação positiva entre os aumentos da faixa etária e do TSH. A elevação do TSH pode chegar a mais de 20%, sendo que a grande maioria apresenta hipotireoidismo subclínico (HSC). Essa elevação ocorre também na população idosa sem doença autoimune tireoidiana, sugerindo que faça parte do processo fisiológico relacionado ao envelhecimento...

The world population is aging and the interest in the study of association between thyroid dysfunctions and aging process is also increasing. There are evidences that serum TSH levels are higher in the elderly population, with a positive relationship between age and TSH. The prevalence of TSH elevations can reach over 20%, and the vast majority has subclinical hypothyroidism (SCH). This elevation of TSH occurs also in the elderly population without autoimmune thyroid disease, suggesting that it could be part of a physiological process related to aging...

Humans , Male , Female , Aged , Hypothyroidism/diagnosis , Hypothyroidism/therapy , Motor Activity/physiology , Cardiovascular Diseases/etiology , Aging/physiology , Longevity , Thyrotropin/analysis , Thyrotropin/blood , Thyroxine/administration & dosage , Thyroxine/therapeutic use
Rev. cuba. endocrinol ; 21(1)ene.-abr. 2010.
Article in Spanish | LILACS | ID: lil-575501


La determinación de tiroglobulina sérica se emplea, sobre todo, como marcador tumoral en el seguimiento posoperatorio de pacientes con cáncer diferenciado del tiroides. Lamentablemente, los métodos de tiroglobulina sérica presentan gran variabilidad en sus cualidades analíticas y padecen problemas técnicos que repercuten sobre la utilidad clínica de esta prueba. Para cuantificar tiroglobulina sérica se emplean 2 tecnologías diferentes: los iniciales radioinmunoensayos competitivos y los mßs recientes métodos inmunométricos no competitivos. Estos últimos son más propensos a sufrir las interferencias provocadas por la presencia de autoanticuerpos tiroglobulina y anticuerpos heterofílicos, a pesar de brindar los beneficios técnicos relativos al uso de reactivos no isotópicos, menor volumen de muestra, tiempos de incubación más cortos, así como mejor sensibilidad y facilidad de automatización. Resulta esencial que los clínicos conozcan y comprendan las limitaciones técnicas inherentes a la determinación de tiroglobulina sérica y su repercusión sobre la utilidad clínica de esta, con la finalidad de hacer un uso efectivo y eficiente de esta prueba en el seguimiento posoperatorio de pacientes con cáncer diferenciado del tiroides(AU)

The serum thyroglobulin assessment is used mainly as tumor marker during the postoperative follow-up of patients presenting with thyroid differentiated cancer. Progressively, the serum thyroglobulin methods have much variability in its analytical qualities and also have technical problems affecting on the technical usefulness of this test. To quantify the serum thyroglobulin we used two different technologies: the initial competitive radioimmunoassays and the most recent non competitive inmunometrical methods. These latter are more prone to have interferences provoked by presence of thyroglobulin antibodies and heterophilic antibodies despite to offer technical beneficial relative to use of non-isotopic reagents, a lower sample volume, shorter incubation times, as well as a better sensitivity and feasibility of automation. It is essential that clinicians know and understand the technical limitations inherent of serum thyroglobulin assessment and its repercussion on its clinical usefulness to an effective and efficient use of this test during the postoperative follow-up of patients presenting thyroid differential cancer(AU)

Humans , Thyroglobulin/administration & dosage , Thyroid Neoplasms/diagnosis , Thyrotropin/analysis
Córdoba; s.n; 2010. 114 p. ilus, ^c29 cm, ^eCD ROM Tesis Digitalizada.
Thesis in Spanish | LILACS | ID: lil-607241


ANTECEDENTES: La detección del hipotiroidismo congénito (HC) por el screening neonatal evita la morbilidad física con retardo mental. El screening del Hospital Privado deCórdoba (HPCba) utiliza como marcador bioquímico TSH sérica= 10 μU/ml y T4 como complemento. HIPÓTESIS: Es un método eficaz en el screening neonatal el uso de TSHsérica con un nivel de corte apropiado y rangos de referencia acorde a la edad. OBJETIVOS: Evaluar la capacidad de TSH sérica para detectar HC y obtener la frecuencia de HC. Definir el valor óptimo de corte y valores de referencia para TSH sérica. Identificar factores de riesgoque inciden sobre la elevación de TSH. MATERIALES Y MÉTODOS: Todos los recién nacidos (RN) entre años 2001 y 2007. Se excluyeron TSH procesadas en otro laboratorio,menores de 0.5 mUI/ml, y las obtenidas después de 20 días de vida. Fueron excluidos los RN fallecidos antes del mes y con menos de 1.500 grs. La población en estudio se dividió en 3 grupos: total, grupo problema (TSH >10) y grupo control. Las herramientas estadísticas: pruebas t de Student, análisis de regresión logarítmica, curvas ROC, media, desvío estándar y logaritmo natural y antinatural. RESULTADOS: Total de RN 7.869, fallecidos 43, excluidos980. De los 6.846 estudiados 6.546 (87,47%) presentaron TSH <10 μU/ml y 300 (3,83%) TSH >10 μU/ml. Del total de RN se confirmó HC en 6 (0,07%) ubicando la incidencia en1:1.304 con igual relación femenino-masculino. La media de TSH sérica fue de 4,42 (± 4,17) μU/ml. El 75% fueron testeados a los 5,85 (± 2,58 días). Con el valor de corte utilizado (TSH=10 μU/ml) 4,38% fueron falsos positivos, reducidos a 1,28% con el uso complementario de T4; este elevado porcentaje obligó a un exhaustivo análisis que permitió sugerir un nuevo valor de TSH sérica= 20 μU/ml. Se observó relación inversa entre edad del RN y la posibilidad de tener TSH >10 μU/ml, por lo que se definieron rangos de referencia para TSH sérica según edad del RN...

Humans , Infant, Newborn , Child , Infant, Newborn , Intensive Care Units, Neonatal , Neonatology , Thyrotropin/analysis , Thyrotropin/metabolism , Toxoplasmosis, Congenital/prevention & control , Substance-Related Disorders/diagnosis
Rev. biol. trop ; 57(4): 1049-1058, dic. 2009. ilus
Article in English | LILACS | ID: lil-637743


The endocrine system controls and coordinates behavioral, biochemical, and physiological processes through signal mechanisms using neuropeptides or products of neurosecretory cells. Among invertebrates, this system is poorly studied in rotifers, in which estrogens and androgens significantly affect sexual reproduction. This is the first report of the presence of the Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), Thyroid Stimulating Hormone (TSH) and Prolactin (PRL) in rotifers. Analyses included the avidin-biotin-peroxidase complex method with primary antibodies LH (Anti-Rat LH serum for RIA), PRL (Anti-Rat PRL serum for RIA), FSH (Anti-Rat FSH serum for RIA) and TSH (Anti-Rat TSH serum for RIA). These hormones were found in females, males and parthenogenetic and sexual eggs of the freshwater Brachionus calyciflorus. The immunoreactivity of FSH, LH, TSH and PRL in females was observed in: ovaries, cerebrum, mastax, stomach, lorica, and the stomach gland. However, in males LH was observed only at the trochal disk and cerebrum. The hormones FSH, TSH and PRL, were observed in testicles, contractil vesicles, and cementary gland of males. Regarding amictic or parthenogenetic eggs, the hormones LH, FSH, TSH, and PRL were located mainly in the micromeres, and the staining in the macromeres was weak. On the other hand, in the mictic or sexual eggs the inner shell is stained for the hormones PRL and LH, opposite to the staining of FSH and TSH, located mainly in the embryo. In general, immuno-reactivity was observed in areas important for the reproductive, excretory, digestive and developmental processes. Rev. Biol. Trop. 57 (4): 1049-1058. Epub 2009 December 01.

Se logró detectar la presencia de las hormonas: Hormona Luteinizante (LH), Hormona Folículo Estimulante (FSH), Hormona Estimulante de la Tiroides (TSH) y Prolactina (PRL) en Brachionus calyciflorus siendo el primer reporte de la presencia de dichas hormonas en rotíferos. Estas hormonas fueron identificadas por un método inmunológico-histológico-químico usando el complejo avidina-biotina- peroxidasa con los siguientes anticuerpos primarios: LH (Anti-Rata LH suero para RIA), PRL (Anti-Rata PRL suero para RIA), FSH (Anti-Rata FSH suero para RIA) y TSH (Anti-Rata TSH en suero para RIA). Estas hormonas se encontraron en las hembras, machos, huevos partenogenéticos y huevos sexuales del rotífero dulceacuícola B. calyciflorus. La reactividad inmunológica de FSH, LH, PRL y TSH en las hembras se observó en ovarios, cerebro, mástax, estómago, lorica, y la glándula del estómago. Sin embargo, en machos, la LH se observó sólo en el disco trocal y cerebro mientras que las hormonas FSH, PRL y TSH, se observaron en testículos, vesícula contráctil, y la glándula cementaria. En cuanto a los huevos partenogenéticos o amícticos, las hormonas LH, FSH, TSH, y PRL, se encontraron principalmente en los micrómeros, y en los macrómeros la tinción es débil. Por otra parte, el huevo sexual o míctico muestra reactividad inmunológica en la cubierta interior del huevo para las hormonas LH y PRL, lo contrario para FSH y TSH, las cuales se observaron principalmente en el embrión. La reactividad inmunológica fue observada, en general, en áreas importantes para los procesos reproductivos, excretorios, digestivos y del desarrollo.

Animals , Female , Male , Rats , Gonadotropins, Pituitary/analysis , Rotifera/chemistry , Thyrotropin/analysis , Follicle Stimulating Hormone/analysis , Luteinizing Hormone/analysis , Ovum , Prolactin/analysis
Rev. Hosp. Ital. B. Aires (2004) ; 28(2): 57-62, dic. 2008. graf, tab
Article in Spanish | LILACS | ID: lil-575085


Presentamos la experiencia de la pesquisa de hipotiroidismo congénito (HC) en la que se evaluaron 37.750 neonatos nacidos en el Hospital Italiano de Buenos Aires y su filial de San Justo entre los años 1989 y 2007. Se midió tirotrofina por radioinmunoensayo. Se detectaron 25 neonatos con HC: 10 definitivos, 2 transitorios y 13 no confirmados aún; como resultado se registró una prevalencia de HC definitivo de 1/3 775. La causa más frecuente de HC definitivo fue la disgenesia tiroidea. El permanente ajuste de los valores de corte de TSH hizo posible disminuir el porcentaje de falsos positivos y consecuentemente el porcentaje de recitación en un 91.3% en este período. Enfatizamos la importancia de la detección temprana del HC a fin de instaurar un tratamiento precoz y evitar así el retardo mental y neurológico que esta enfermedad produce.

To assess the occurrence of congenital hypothyroidism (CH), 37 750 newborns were evaluated at Hospital Italiano deBuenos Aires and its affiliated hospital in San Justo between 1989 and 2007. Determination of thyrotropin by radioimmunoassay allowed for the detection of 25 newborns with CH of whom 10 were definitive, 2 transient and 13 without confirmation at the current time. The prevalence of definitive CH was 1/3775 newborns, being thyroid dysgenesis the most common cause of the disease. A continuous adjustment of TSH threshold values resulted in a decrease of false positive cases with a consequent reduction of 91.3% on office visits for follow-up during this period.We remark on the importance of an early detection of CH so that treatment can be initiated to prevent mental and neurological retardation associated with the disease.

Humans , Male , Female , Infant, Newborn , Early Diagnosis , Congenital Hypothyroidism/diagnosis , Hypothyroidism/prevention & control , Receptors, Thyrotropin , Thyroid Dysgenesis , Thyrotropin/analysis
Arq. bras. endocrinol. metab ; 52(9): 1448-1451, Dec. 2008. tab
Article in English | LILACS | ID: lil-504549


The objective of the present study was to evaluate bone and cardiac abnormalities and symptoms and signs of thyroid hormone excess in women with subclinical hyperthyroidism (SCH) aged < 65 years. Forty-eight women with SCH were evaluated. The control group consisted of 48 euthyroid volunteers. The mean symptom rating scale score was significantly higher in patients. Cardiac involvement, both morphological and affecting systolic and diastolic functions, was also observed in patients. Women with SCH showed a significant increase in serum markers of bone formation and resorption. In addition, bone mineral density (BMD) was lower in the femoral neck but not in the lumbar spine in patients before menopause, whereas a lower BMD was observed at both sites in postmenopausal patients. SCH is not completely asymptomatic in women aged < 65 years, and is associated with heart abnormalities and with increased bone turnover and reduced BMD even before menopause.

O objetivo deste estudo foi avaliar as anormalidades ósseas e cardíacas, sintomas e sinais de excesso de hormônio tireoidiano em mulheres com hipertireoidismo subclínico (HSC) e menos de 65 anos de idade. Quarenta e oito mulheres com HSC foram avaliadas. O grupo-controle consistiu de 48 voluntárias eutireoidianas. A média do escore de sintomas foi significativamente maior em pacientes que em controles. Comprometimento cardíaco, morfológico e afetando as funções sistólica e diastólica, também foi observado. Mulheres com HSC apresentaram significativo aumento dos marcadores séricos de formação e reabsorção óssea. A densidade mineral óssea (DMO) foi menor no colo de fêmur, mas não em coluna lombar em mulheres antes da menopausa; enquanto e em ambos os sítios nas mulheres pós-menopausadas. HSC não é inteiramente assintomático em mulheres com menos de 65 anos, está associado a anormalidades cardíacas morfológicas e funcionais, incremento da remodelação óssea, e menor DMO, mesmo antes da menopausa.

Adult , Female , Humans , Middle Aged , Bone Diseases, Metabolic , Heart Diseases , Hyperthyroidism , Postmenopause/metabolism , Thyrotropin/analysis , Bone Density , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/metabolism , Bone Diseases, Metabolic/physiopathology , Case-Control Studies , Femur Neck , Heart Diseases/etiology , Heart Diseases/metabolism , Heart Diseases/physiopathology , Hyperthyroidism/complications , Hyperthyroidism/metabolism , Hyperthyroidism/physiopathology , Premenopause/metabolism , Statistics, Nonparametric
Rev. argent. endocrinol. metab ; 45(5): 195-205, oct.-dic. 2008. tab
Article in Spanish | LILACS | ID: lil-641943


Objetivo: En el hipotiroidismo tanto clínico como subclínico se han descripto alteraciones en el metabolismo lipídico, entre ellas la disminución de colesterol de lipoproteínas de alta densidad (HDL-C). Considerando el rango normal de TSH entre 0.4-3.0 μUI/ml y valores normales altos entre 2.0 y 3.0 μUI/ml, nosotros investigamos la hipótesis de que niveles normales altos de TSH e insulinorresistencia (IR) se encuentran relacionados con HDL-C bajo en mujeres, en ausencia de otros factores concurrentes. Materiales y métodos: Estudiamos en un estudio transversal a 200 mujeres sanas, edad 18-50 años, eutiroideas, normotensas, con anticuerpos antiperoxidasa (ATPO) negativos, no diabéticas, premenopáusicas, IMC 18.0-25.0 Kg/m2, perímetro de cintura ≤ 88 cm; perímetro de cuello ≤ a 35 cm. Se las dividió en 4 grupos, cada uno compuesto por 50 mujeres: Grupo 1 (G1) TSH ≥ 2μU/ml, IR; grupo 2 (G2) TSH ≥ 2μU/ml, no IR; grupo 3 (G3): TSH 0,40 a 1,99 μU/ml, IR; Grupo 4 (G4) TSH 0,40 a 1,99 μU/ml, no IR. Se les midió lípidos, TSH, T4 total y libre (T4L), glucosa e insulina basal y posprandial, índices HOMA y QUICKI y volumen tiroideo (VT). Resultados: Observamos que en el G1 el nivel de HDL-C (46,7± 8,1 mg/dl) fue significativamente menor que en los restantes grupos. (vs G2: 56,8 ± 8,6 mg/dl; vs G3: 51,2 ± 7,6 mg/dl y vs G4: 56,5 ± 9,1 mg/dl. (p<0,01). La frecuencia de pacientes con HDL-C bajo en G1 fue significativamente mayor que en los restantes grupos (vs G2: OR 1,83, IC: 1,23-2,70; vs G3: OR 1,49, IC: 1,04-2,31; vs G4: OR 1,90, IC: 1,29-2,81) . No encontramos diferencias significativas en los niveles de HDL-C entre los restantes grupos. Conclusiones: Observamos en mujeres eutiroideas con TSH normal alta insulinorresistentes, sin otros factores concurrentes, niveles de HDL-C significativamente más bajos que en mujeres no insulinorresistentes y que en mujeres insulinorresistentes con TSH normal baja.

It has been described abnormalities in lipid metabolism in clinical and subclinical hypothyroidism, including the reduction of high-density lipoprotein cholesterol (HDL-C). Considering the normal range for TSH between 0.4-3.0 uUI / ml and high-normal values between 2.0 and 3.0 uUI / ml, we investigated the hypothesis that in euthyroid women, high-normal TSH levels and insulin resistance (IR) are associated with low HDL-C. We observed in euthyroid women with high-normal TSH and insulin resistance, without other factors, a significantly lower level of HDL-C than in non-insulin or insulin resistance women with low-normal TSH.

Humans , Female , Adolescent , Adult , Middle Aged , Insulin Resistance/physiology , Hypothyroidism/etiology , Cholesterol, HDL/analysis , Reference Values , Thyrotropin/analysis , Lipid Metabolism/physiology , Hypothyroidism/prevention & control , Lipoproteins, HDL/analysis , Cholesterol, HDL/biosynthesis
Rev. argent. endocrinol. metab ; 45(5): 224-243, oct.-dic. 2008. ilus
Article in Spanish | LILACS | ID: lil-641946


El examen PET-TC ha ganado un lugar en el estudio de los tumores de origen endocrino. El marcador metabólico 18F-FDG es el más empleado internacionalmente y el único por el momento en nuestro medio. Las principales limitaciones del método en Endocrinología incluyen la alta diferenciación y baja agresividad de la mayoría de los tumores endocrinos, dificultad en la identificación de lesiones de escasa celularidad y el pequeño tamaño. Las indicaciones para su empleo deben ser precisas debido a que no todos los tumores presentan sustancial avidez por este compuesto por una parte y poder extraer la máxima eficacia diagnóstica del método con adecuadas indicaciones por la otra. La indicación más importante es en pacientes con cáncer diferenciado de tiroides (CDT) con valores de Tg elevados y barridos con 131I negativos. Es aconsejable su indicación con valores de Tg mayores a los 10 ng/ml y con TSH estimulada (endógena o exógena). El objetivo es la localización de las recidivas y metástasis para su exéresis o el empleo de otras terapias alternativas al 131I. Tiene alto valor pronóstico ya que es mayor la fijación de FDG en las lesiones más agresivas. Un paciente con Tg elevada, barrido con 131I negativo y FDG positivo obliga al clínico a actuar más agresivamente para eliminar los focos patológicos, mientras que con FDG negativo puede tener una conducta expectante con controles posteriores. La introducción de otros marcadores emisores de positrones específicos como el 124I, isótopo del Iodo, seguramente aportarán mejores imágenes y diagnósticos. En los tumores neuroendocrinos la FDG tiene limitada aplicación, salvo cuando hay un grado significativo de desdiferenciación. En el cáncer medular de tiroides (CMT) es conveniente indicarlo cuando los niveles de calcitonina superan los 1000 pg/ml con el objeto de localizar el/los sitios de su producción. Con la introducción de radiofármacos más específicos de las diferentes líneas celulares que componen el espectro de los tumores neuroendocrinos con emisores de positrones, tales como 18F-DOPA, 68Ga DOTA, 11C metomidato, 11C-5-hidroxitriptofano, etc., se podrá estudiar con mayor precisión el comportamiento metabólico-molecular de estos tumores.

PET/CT scans have reached an important place in the evaluation of endocrine tumors. The metabolic marker 18F-FDG is the most widespread over the world, and, for the time being, it is the only one available in our country. The limitations of this technique in Endocrinology include high differentiation and low aggressiveness of most endocrine tumors, and low detection rate for low cellularity and/or small lesions. Indications for PET/CT scan in these tumors should be precise, due to the fact that not all of these lesions are significantly glucose-avid and to extract the maximum diagnostic efficacy of this modality to achieve the optimum diagnostic accuracy. The most important indication is DTC with high Tg levels and negative 131I scans. It is advisable to indicate a PET/CT scan in patients with Tg > 10 ng/ml and stimulated TSH (endogenous or exogenous). The aim is to locate recurrencies and metastases in order to remove them, either surgically or by any other therapy alternative to 131I. Due to higher uptake in more aggressive lesions, this study has a high prognostic value. In patients with high Tg levels, negative I-131 scan, and abnormal FDG uptake, the practitioner must act more aggressively in order to remove the pathologic foci, while with a negative FDG -PET scan, the conduct can be expectant, with periodic follow-up. The introduction of other positron-emitting tracers like 124-Iodine, is likely to yield superior quality images and provide better diagnoses. FDG has a limited efficiency in neuroendocrine tumors, unless they show a significant level of desdiffer-entiation. The scan is indicated in MTC, when calcytonin levels are above 1000 pg/ml, in order to locate the tumor sites. With the introduction of more specific positron-emitting radiopharmaceuticals, such as 18F-DOPA, 68Ga DOTA, 11C metomidate, 11C-hidroxytriptophan and others, it will be possible to study the metabolic-molecular behavior of these tumors with a more accurate approach.

Humans , Male , Female , Infant, Newborn , Child, Preschool , Child , Adolescent , Iodine Deficiency/diagnosis , Iodine Deficiency/prevention & control , Goiter, Endemic/diagnosis , Goiter, Endemic/prevention & control , Iodine Deficiency/complications , Thyrotropin/analysis , Population Studies in Public Health , Epidemiological Monitoring , Iodine/urine
Rev. argent. endocrinol. metab ; 45(5): 206-213, oct.-dic. 2008. graf, tab
Article in Spanish | LILACS | ID: lil-641944


El déficit de yodo (IDD) es un problema de Salud Pública que afecta a millones de personas en todo el mundo causando alteraciones en la neuromaduración que pueden ser evitados si se realiza una yodoprofilaxis adecuada. Objetivo: Realizar un monitoreo de IDD en la localidad de Salta Capital, por su ubicación geográfica y hábitos alimentarios con posible consumo regional de sal no iodada. Material y métodos: En 442 escolares (221 mujeres) de 5 a 14 años de edad, se evaluaron: peso, SDS talla y, SDS BMI. Se realizó la palpación tiroidea y el volumen glandular fue clasificado según los criterios de la OMS. En 97 niños se determinó la yoduria en muestras casuales de orina por el método de Sandell y Kolthof modificado. Se analizó la distribución de los niveles de TSH de la pesquisa neonatal (IFMA-DELFIA) realizada en la región de los 18 meses previos al estudio Se aplicaron los criterios de suficiencia iodada establecidos por la OMS/ ICCDD Resultados: La prevalencia de bocio fue de 6.3 %. Los niveles de yoduria fueron: mediana de 127.5 ug/l con 20 % < 50 ug/l. Sólo el 1.6 % de las muestras de TSH neonatal fueron > 5 uU/ml. Cuando se aplicaron los criterios de la OMS la prevalencia de bocio superaba levemente lo esperado para una zona suficiente y los niveles de ioduria correspondían con un aporte iodado adecuado pero marginal en su distribución. La distribución de TSH fue la esperada para una zona suficiente. Conclusión: Si bien el aumento de la prevalencia de bocio podría explicarse por factores ambientales la distribución marginal de la ioduria señala un aporte de yodo suficiente pero con necesidad de supervisión estrecha.

The iodide deficit disorder (IDD) is a worldwide Public Health problem that affects more than a million subjects causing neuromadurative disorders that could be avoided with adequate iodide supply. Objective: To monitor IDD in Salta Capital, due to its geographic location and possible utilization of non iodated salt. Population and methods:. SDSHeight , SDS BMI and weight were assessed in 442 scholars (221 girls) aged 5 to 14. Thyroid volume was evaluated and classified according to WHO criteria. In 97 children iodide urinary concentration was measured in casual urine samples by the modified Sandell and Kolthof method.TSH level's distribution of the neonatal screening performed in the region 18 months prior to this study (n 310) was evaluated. Criteria suggested by WHO to indicate iodide deficiency were applied. Results: Goitre prevalence was 6.3%, Iodide urine median levels were 127.5 ug/l with 20% < 50 ug/l. Only 1.6% of the 310 TSH samples were > 5 μU/ml. Applying WHO criteria goiter prevalence was higher that expected for a iodide sufficient area and urine iodide content was normal but marginal in its distribution. Neonatal TSH levels were the expected for a sufficient area. Conclusion: Although high goiter prevalence could be explained by environmental factors the distribut-ion of urinary iodide points out an adequate but marginal iodide supply underscoring the need of close monitoring.

Humans , Male , Female , Child, Preschool , Child , Adolescent , Iodine Deficiency/diagnosis , Iodine Deficiency/prevention & control , Goiter, Endemic/diagnosis , Goiter, Endemic/prevention & control , Iodine Deficiency/complications , Thyrotropin/analysis , Population Studies in Public Health , Epidemiological Monitoring , Iodine/urine
Säo Paulo med. j ; 126(5): 291-293, Sept. 2008.
Article in English | LILACS | ID: lil-500339


CONTEXT: Hypothyroidism is more prevalent in the elderly and its symptoms can be confused with other changes due to aging. Doctors caring for the elderly need to be attentive to this diagnostic possibility. This case report case is notable not only because it presents a rare complication of hypothyroidism (kidney failure), but also because patients with chronic kidney failure of any etiology may suffer increased renal dysfunction as a result. CASE REPORT: This was a 66-year-old male outpatient with a history of generalized edema over the preceding eight years, with periods of worsening, that was intractable to treatment with diuretics. Physical examination revealed bradycardia (heart rate: 52 bpm), pallor, dry and infiltrated skin, macroglossia, edema in the lower limbs and a palpable thyroid with hard consistency. Laboratory tests showed: creatinine 3.9 mg/dl; urea 95 mg/dl; potassium 6.0 mEq/l; thyroid-stimulating hormone > 100 mUI/ml; triiodothyronine 0.01 ng/dl; free thyroxin 0.01 ng/dl; antithyroglobulin 31 IU/ml (normal values: < 40 IU/ml); antithyroperoxidase 85 IU/ml (normal values: < 15 IU/ml); creatinine clearance 30 ml/min/1.73 m²; and proteinuria 122 mg/24 h. After five months of treatment with thyroxin (100 mcg/day), the patient returned without any symptoms and presented the following test results: urea 48 mg/dl; creatinine 1.4 mg/dl; creatinine clearance 67 ml/min/1.73 m²; potassium 4.2 mEq/l; thyroid-stimulating hormone: 20.85 mUI/ml; free thyroxin: 0.71 ng/dl. Hypothyroidism alone can cause renal impairment or worsen renal function in preexisting illnesses. Its treatment can stabilize the clinical condition, or possibly improve it.

CONTEXTO: O hipotireoidismo tem uma prevalência elevada em idosos e sua sintomatologia pode ser confundida com alterações próprias do envelhecimento, obrigando o médico que atende o idoso sempre estar atento a essa possibilidade diagnóstica. O relato deste caso chama atenção não somente para uma rara complicação do hipotireoidismo, a insuficiência renal, como para o fato de pacientes portadores de insuficiência renal crônica de qualquer outra etiologia poderem ter piora da disfunção renal devido a esse quadro. RELATO DO CASO: Homem de 66 anos foi atendido em nosso ambulatório com história de edema generalizado há oito anos, com períodos de piora, refratário a tratamento com diuréticos. Ao exame físico encontrava-se bradicárdico (freqüência cardíaca 52 bpm), hipocorado; pele ressecada e infiltrada; macroglossia; edema de membros inferiores; tireóide palpável e de consistência endurecida. Exames laboratoriais mostraram: creatinina 3,9 mg/dl; uréia 95 mg/dl; potássio 6,0 mEq/l; hormônio estimulante da tireóide, TSH > 100 mUI/ml; T3 0,01 ng/dl; T4 0,01 ng/dl; anti-tireoglobulina 31 UI/ml (< 40 UI/ml); anti-tiroperoxidase 85 UI/ml (< 15 UI/ml); clearence de creatinina 30 ml/min/1,73 m²; proteinúria 122 mg/24 h. Após cinco meses de tratamento com tiroxina 100 mcg/dia o paciente retornou ao ambulatório assintomático, apresentando os seguintes exames: uréia 48 mg/dl; creatinina 1,4 mg/dl; clearence de creatinina 67 ml/min/1,73 m²; potássio 4,2 mEq/l; TSH 20,85 mUI/ml; T4 livre 0,71 ng/dl. CONCLUSÃO: O hipotireoidismo per se pode levar a insuficiência renal ou piorar a função renal em doenças preexistentes. Seu tratamento pode reverter essa condição clínica ou, pelo menos, melhorá-la.

Aged , Humans , Male , Hypothyroidism/complications , Kidney Failure, Chronic/etiology , Hypothyroidism/diagnosis , Treatment Outcome , Thyrotropin/analysis
Rev. med. nucl. Alasbimn j ; 10(41)jul. 2008. ilus, tab
Article in Spanish | LILACS | ID: lil-495992


La búsqueda un método alternativo a la rh-TSH para estimular el aumento de la TSH sérica previo al tratamiento con 131I en pacientes con CDT operados con reducción del tiempo del hipotiroidismo pre ablativo fue el propósito del trabajo que iniciamos en el año 2001 en el Paraguay utilizando múltiples dosis de TRH para estimular la TSH endógena de los pacientes para luego lograr la ablación del remanente tiroideo con 131I. Se conoce que la inyección de una dosis única de 200µU de TRH por vía EV logra el aumento de la TSH endógena en los pacientes con carcinoma diferenciado de tiroides logrando elevar la TSH entre 30 - 35 mUI/L al final de la primera hora , sin embargo, no se cuentan con datos estadísticos de los efectos de múltiples inyecciones de TRH aplicadas por vía EV o por vía IM en los pacientes operados de tiroides por CDT previamente a la ablación con 131I. Material y Método: Desde el 2001al 2007 doscientos pacientes operados por CDT fueron estudiados por este método en el Centro de Diagnostico y Tratamiento Nuclear (CEDIN), 120 correspondieron a cáncer papilar y 80 a cáncer folicular. Ciento ochenta no presentaron metástasis a distancia y 20 presentaron metástasis en cuello, tórax, pelvis y columna dorsal. Tiroidectomía total se realizó en 120 y lobectomía total e itsmectomía más hemilobectomía del lado contra lateral en 80. Todos fueron tratados con dosis ablativas (100 mCi (3.700 mBq) de 131I excepto aquellos con metástasis que recibieron 150 mCi (5.500 mBq) previa estimulación con TRH por vía EV en dos dosis diarias por dos días con previa suspensión de L-tiroxina por 25 días antes del tratamiento reemplazándola por triyodotironina 25 mcg/día por 15 días tras lo cual también fue suspendida 10 días antes de la estimulación con TRH y el tratamiento con 131I. Dos pacientes con metástasis recibieron otra dosis extra de 150 mCi (5.550 MBq) 6 meses después...

The search of an alternative method to the rh-TSH to stimulate endogenous rising of TSH previous to thyroid ablation with 131I in patients with CDT operated. The purpose of the work began in 2001 in Paraguay using multiple dose of TRH IV (200µU of TRH Threlea® Argentina) to stimulate the own TSH of patients previous to 131I ablation. It is known that the injection of an unique dose of 200µU of TRH IV achieves the increasing of the endogenous TSH in patients with differentiated thyroid carcinoma up to 30 - 35 mUI/L at the end of the first hour, however, there is not statistical data of the effects of multiple injections of TRH applied IV or IM in operated patients of DTC previous to the ablation with 131I. Since 2001-2007, two hundred patients operated for DTC were studied by this method, 120 were papillary cancer and 80 follicular cancer. One hundred eighty did not have distance metastasis and 20 presented metastasis in thorax, pelvis and dorsal spine. Total thyroidectomy was carried out in 120 and total lobectomy with itsmectomy plus hemilobectomy of the other lobe in 80. All were treated with ablative dose of 100 mCi (3.700 mBq) of 131I, except those with metastasis which receive 150 mCi (5.500 mBq) with the previous stimulation with TRH IV with two daily dose for three days with previous suspension of L-tiroxine for 25 days and replaced by triyodotiroxine 25 mcg/d for 15 days with suspension 10 days before the stimulation with TRH and treatment with 131I. Two patients with metastasis received another extra dose of 150 mCi (5.550 MBq) 6 months later. One presented uptake in thyroid bed one year after the ablation received a new ablative dose of 100 mCi (3.700 mBq) of 131I. All the patients were interned and isolated by 48 hours. Twenty feminine patients had later pregnancies in 1-3 years after their ablative dose with healthy products. TSH was measured during the stimulation with TRH in all patients...

Humans , Male , Female , Adenocarcinoma, Follicular , Carcinoma, Papillary , Thyrotropin-Releasing Hormone/administration & dosage , Thyrotropin-Releasing Hormone/pharmacology , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/radiotherapy , Thyrotropin , Control Groups , Injections, Intravenous , Neoplasm Metastasis/radiotherapy , Thyroid Neoplasms/surgery , Thyroid Neoplasms/pathology , Iodine Radioisotopes/therapeutic use , Time Factors , Thyroglobulin/analysis , Thyroglobulin , Thyrotropin/analysis
Rev. méd. Chile ; 136(7): 831-836, jul. 2008. tab
Article in Spanish | LILACS | ID: lil-496002


Background: Growth hormone (GH) producing adenomas, frequently express several hormones. This condition could confer them a higher proliferative capacity. Ki-67 is a nuclear protein antigen that is a marker for proliferative activity. Aim: To measure the immunohistochemical hormone expression in pituitary adenomas, excised from patients with acromegaly. To determine if the pluríhormonal condition of these adenomas is associated with a higher proliferative capacity, assessed through the expression of Ki-67. Material and methods: Forty one paraffin embedded surgical samples of pituitary adenomas from patients with acromegalia were studied. Immunohistochemistry for GH, prolactin (PRL), follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), adrenocorticotropin (ACTH) and for the expression of Ki-67 was carried out. Results: All samples were positive for GH. Twenty seven had positive staining for PRL, 12 had positive staining for glycoproteic hormones and 11 for PRL and one or more glycoproteic hormones. Mean staining for Ki-67 was Z.6±3.3 percent. There were no differences in the expression of this marker between mono or pluríhormonal tumors. The expression was neither associated with extrasellar extensión. Conclusions: Half of GH producing pituitary adenomas are pluríhormonal. There are no differences in the expression of Ki-67 between mono and plurihormonal adenomas.

Adult , Aged , Female , Humans , Male , Middle Aged , Adenoma/metabolism , Growth Hormone-Secreting Pituitary Adenoma/metabolism , Human Growth Hormone/metabolism , /metabolism , Neoplasm Proteins/metabolism , Pituitary Neoplasms/metabolism , Acromegaly/physiopathology , Acromegaly/surgery , Adrenocorticotropic Hormone/analysis , Follicle Stimulating Hormone/analysis , Immunohistochemistry , Neoplasm Proteins/analysis , Prolactin/analysis , Proliferating Cell Nuclear Antigen/analysis , Statistics, Nonparametric , Thyrotropin/analysis
Iranian Journal of Allergy, Asthma and Immunology. 2008; 7 (1): 31-36
in English | IMEMR | ID: emr-87281


Type 1 diabetes mellitus is frequently associated with autoimmune thyroid disease [ATD].Genetic susceptibility for autoantibody formation in association with ATD and type 1 diabetes mellitus has been described with varying frequencies, but there is still debate about its prevailing situation in Iran. We have therefore investigated the prevalence of anti-thyroid peroxidase [anti-TPO] and anti thyroglubolin [Anti TG] antibodies in type 1 diabetic patients, and compared the effect of age and sex on the thyroid autoimmunity in patients with type 1 diabetes mellitus in Iran. Ninety one subjects with type 1 diabetes mellitus and one hundred and sixty three unrelated normal controls under the age of thirty years were recruited for the detection of anti-TPO and anti-TG. Radio Immuno Assay and chemiluminescence methods were used for anti-TPO and anti-TG detection respectively. Among 91 type 1 diabetic patients, 36 [39.6%] were positive for anti-TPO and 27[30%] were positive for antiTG. Anti-TPO antibodies were detected only in 6.7% of control group. Comparing with those without thyroid autoimmunity, there was a female preponderance for the type 1 diabetic patients with thyroid autoimmunity [female: male, 28:14 vs. 28:20 respectively]. Among the type 1 diabetic patients those with thyroid autoimmunity, tended to be older [p: 0.04] and to have higher TSH concentration [p: 0.03]. Patients with high anti-TPO levels had longer duration of diabetes [P: 0.02]. The presence of anti-TPO in 39.6% of our type 1 diabetic patients comparing with 8.5% of normal subjects confirmed the strong association of ATD and type 1 diabetes mellitus

Humans , Male , Female , Thyroid Function Tests , Thyroid Diseases , Age Factors , Sex Factors , Iodide Peroxidase/analysis , Autoantibodies , Thyroglobulin/analysis , Autoimmune Diseases , Thyrotropin/analysis , Radioimmunoassay , Prevalence , Glycated Hemoglobin A
Article in English | IMSEAR | ID: sea-43750


A cross-sectional study of thyroid function, free thyroxine (FT) and thyrotropin (TSH) concentrations, was carried out in 51 transfusion-dependent beta-thalassemic patients receiving suboptimal iron-chelating therapy. Nine patients had normal FT4 levels with elevated TSH levels (5.9-15.6 mLU/L), consistent with the diagnosis of compensated primary hypothyroidism and giving a prevalence of abnormal thyroid function of 17.6%. All patients with abnormal thyroid function had negative thyroid antibodies. No particular risk factor for abnormal thyroid function could be identified. Of the nine patients with compensated primary hypothyroidism, one patient showed a further increase in TSH level after 1 year of follow-up. The results of the present study emphasize the importance of thyroid function monitoring in hypertransfused beta-thalassemic patients.

Adolescent , Age Factors , Blood Transfusion , Child , Cross-Sectional Studies , Female , Humans , Iron Chelating Agents/therapeutic use , Male , Risk Factors , Thyroid Diseases/diagnosis , Thyroid Gland/drug effects , Thyrotropin/analysis , Thyroxine/analysis , beta-Thalassemia/drug therapy
Rev. med. nucl. Alasbimn j ; 9(34)oct. 2006. ilus, tab
Article in Spanish | LILACS | ID: lil-445750


Thyroid disease is frequent in Paraguay, a country with a prevalence of goiter 48,6 percent in general population located in the center of South America. Grave’s disease constitutes the most common thyroid hyperfunction observed whose treatment can be carried out with medication (propiltiouracil, metimazol, etc.), surgery or iodine 131(131I) We analyzed 70 patients this type of hyperthyroidism treated with the 131I, in its clinical aspect pre and post treatment, ultrasound and nuclear scan findings of the gland thyroid, the hormonal respond Ft4, T3, TSH, thyroid antibodies TPOab, TGab, TRab. Besides the diffuse classic image observed in the thyroid scan and by ultrasonography of the gland, in Grave’s disease, 4 types of images were identified with nodules (multinodular, hot nodule, cold nodule and miliar). The group with diffuse increase in size form was the most numerous (50 percent) continued by the variety multinodular (30 percent), Marin-Lenhart’s Sx (hot nodule) 14 percent, miliary 3 percent, and cold nodule 3 percent. Three months after the treatment with the radioiodine was observed the decrease of the size and thyroid volume in 68 percent of the patients, thyroid uptake with 131I diminished in 75 percent. All patients had an increase of weight of 20 percent and 87 percent of then were feminine. The signs and symptoms were normalized in 88,5 percent of the patients. The levels of FT4 were normalized in 73, 8 percent, T3 in 66 percent, TSH in 47,7 percent, TPOab in 83 percent, TGab in 90 percent, and TRab in 84 percent. A received a single dose of 131I was used it in 93 percent of the patient The cost of the 131I in the Clinic Hospital was half of the cost of the surgery, and at private level the fourth part but cheap.

Humans , Male , Adult , Female , Middle Aged , Graves Disease , Graves Disease/drug therapy , Graves Disease , Thyroid Gland , Thyroid Gland , Thyroid Gland , Iodine Radioisotopes/therapeutic use , Antibodies/analysis , Thyroid Gland/metabolism , Thyroid Nodule , Thyroid Nodule , Paraguay , Iodine Radioisotopes/pharmacokinetics , Treatment Outcome , Technetium , Thyrotropin/analysis , Thyroxine/analysis , Triiodothyronine/analysis